Highlights include:
• How MRD is reshaping drug development and accelerating innovation
• The evolution of next-generation and targeted therapies with the goal of achieving deeper and more durable remissions
• New thinking on “hit hard early” vs “save the best for last” treatment strategies
• The impact of race, biology, and access on outcomes—and what’s changing that trajectory

If you want to understand the science, urgency, and humanity driving today’s breakthroughs, this episode is your front-row seat to the bleeding edge of discovery.

About the Experts

Dr. Paul Richardson

Dr. Paul Richardson is an internationally recognized visionary in hematology and oncology whose trailblazing research at Dana-Farber Cancer Institute and Harvard Medical School has driven therapeutic revolutions in multiple myeloma, transforming patient outcomes and defining today’s standards of care. In addition to his involvement in the approval of nearly every major therapy for the disease over the past two decades, he is also one of the most prolific and cited experts in the field, with nearly 500 original articles and 400 reviews.

Dr. Richardson is a paid consultant for BMS.

Dr. Joseph Mikhael
Dr. Joseph Mikhael has revolutionized and broadened access to world-class myeloma care globally through his pioneering leadership at TGen and the International Myeloma Foundation and as principal investigator of numerous groundbreaking clinical trials, setting new benchmarks in innovation, impact, and equity. Celebrated as a dynamic champion for underserved communities, an award-winning educator, and a masterful communicator, Dr. Mikhael has authored over 150 influential scientific articles and was recently recognized among America’s Top 100 Doctors for his transformational contributions to the field.

Dr. Mikhael was not compensated for his participation.

Dr. Mecide Gharibo

Dr. Mecide Gharibo is an innovative hematology leader whose passion for transforming patient care extends from academic clinical expertise at Rutgers Cancer Institute to launching breakthrough therapies as Global Head of Hematology at Bristol Myers Squibb. Renowned for advancing life-saving treatments and optimizing patient access, Dr. Gharibo’s clinical excellence and senior pharmaceutical leadership have fueled medical innovation and set new standards for care through a proven record of successful therapy approvals.

Dr. Gharibo is an employee of BMS.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.